Emanuela Marchesi

Emanuela Marchesi

Istituti Ortopedici Rizzoli - Bologna / Italy
Medical and Health Sciences / Orthopedics and Traumatology
AD Scientific Index ID: 4984829
person_outline Emanuela Marchesi's MOST POPULAR ARTICLES
1-) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label …A Gronchi, S Ferrari, V Quagliuolo, JM Broto, AL Pousa, G Grignani, ...The Lancet Oncology 18 (6), 812-822, 20174542017
2-) Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialG Grignani, E Palmerini, V Ferraresi, L D\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Ambrosio, R Bertulli, SD Asaftei, ...The lancet oncology 16 (1), 98-107, 20153282015
3-) Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsA Gronchi, E Palmerini, V Quagliuolo, J Martin Broto, A Lopez Pousa, ...Journal of Clinical Oncology 38 (19), 2178-2186, 20202032020
4-) Photoreduction of the fluorescent dye 2′-7′-dichlorofluorescein: a spin trapping and direct electron spin resonance study with implications for oxidative stress measurementsE Marchesi, C Rota, YC Fann, CF Chignell, RP MasonFree Radical Biology and Medicine 26 (1-2), 148-161, 19992031999
5-) Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long?E Palmerini, NS Chawla, S Ferrari, M Sudan, P Picci, E Marchesi, ...European Journal of Cancer 76, 118-124, 20171642017